NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 13.74 against a street estimate of 13.60 — a beat of 1.0%.
with an average price target of ₹2,762.79.
| Holder | Stake |
|---|---|
| NPS Trust- A/C LIC Pension Fund Scheme - State Gov | 2.65% |
| Nippon Life India Trustee Ltd-a/c Nippon India Ret | 2.45% |
| SBI Esg Exclusionary Strategy Fund | 1.49% |
| Aditya Birla Sun Life Mutual Fund - Aditya Birla S | 1.21% |
| Government Pension Fund Global | 1.06% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call MANKIND PHARMA LIMITED – Q1 FY27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Total Revenue: INR 4,031 crores, up 13% year-on-year (INR 3,570 crores in | 2026-08-04 |
| Investor presentation MANKIND PHARMA LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Revenue from Operations: INR 4,031 Cr in Q1 FY27, up 12.9% YoY from INR 3, | 2026-07-30 |
| Annual report FY2026 MANKIND PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • 35th Annual General Meeting scheduled for Tuesday, August 4, 2026 at 3:30 P.M. (IST) vi | 2026-07-09 |
| Q4 FY26 earnings call MANKIND PHARMA LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 revenue: INR 3,443 crores (11.8% YoY growth) vs INR 3,079 crores in Q4 FY25 • FY | 2026-05-26 |
| Quarterly results · Q4 FY26 MANKIND PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue from Operations: ₹10,421.18 crores (vs ₹9,507.41 crores in FY2 | 2026-05-19 |
| Investor presentation MANKIND PHARMA LIMITED – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR 14,278 Cr – 17.0% YoY growth (domestic INR 12,217 Cr up 14. | 2026-05-19 |
| Q3 FY26 earnings call MANKIND PHARMA LIMITED – Q3 & 9M FY26 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 3,567 crores, up 11.5% YoY (Q3 FY25: INR 3,199 c | 2026-02-09 |
| Quarterly results · Q3 FY26 MANKIND PHARMA LIMITED – Q3 FY26 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 3,567 Crore, up 11.5% YoY • Q3 FY26 Adjusted EBIT | 2026-02-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of majority stake in Armed Cell Therapeutics for strategic CAR-T therapy entry Mankind Pharma Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therap | 2026-10-15 |
| Acquisition announced Mankind Pharma Limited has informed the Exchange about Acquisition | 2026-10-15 |
| Acquisition of another business or entity announced Mankind Pharma Limited has incorporated a wholly owned subsidiary company in the Netherlands named 'Mankind Pharma (Netherlands) B.V.' on August 13, 2026. This was a previously disclosed pla | 2026-08-13 |
| Final update on stake sale of Broadway Hospitality Services Final update on Stake Sale of Broadway Hospitality Services Private Limited | 2026-07-27 |
| Acquisition of another business announced Mankind Pharma Limited has informed the Exchange about Acquisition | 2026-07-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mankind Pharma Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.